Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
ValidSEARCH
An Observational Cohort Study to Validate SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
1 other identifier
observational
150
1 country
8
Brief Summary
Potential outcomes after PE occur on a spectrum: complete recovery, exercise intolerance from deconditioning/anxiety, dyspnea from concomitant cardiopulmonary conditions, dyspnea from residual pulmonary vascular occlusion, chronic thromboembolic disease and chronic thromboembolic pulmonary hypertension. Although a battery of advanced diagnostic tests could distinguish each of those conditions, the yield of individual tests among all post- PE patients is low enough that routine testing of all PE patients is not typically performed. Although the various possible post-PE outcomes have enormous implications for patient care, they are rarely distinguished clinically. Perhaps for this reason, chronic conditions after PE are rarely (if ever) used as endpoints in randomized clinical trials of acute PE treatment. The proposed project will validate a clinical decision tree to distinguish among the various discrete outcomes cost-effectively through a hierarchical series of tests with the acronym SEARCH (for symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging and hemodynamics). Each step of the algorithm sorts a subset of patients into a diagnostic category unequivocally in a cost-effective manner. The categories are mutually exclusive and collectively exhaustive, so that each case falls into one, and only one, category. Each individual test used in the algorithm has been clinically validated in pulmonary embolism patients, including the cardiopulmonary exercise test (CPET) technique that the investigators developed and validated. However, the decision tree approach to deploying the tests has not yet been validated. Aim 1 will determine whether the SEARCH algorithm will yield concordant post-PE diagnoses when multiple reviewers independently evaluate multiple cases (reliability). Aim 2 will determine whether the post-PE diagnoses are stable, according to the SEARCH algorithm, between the first evaluation and the subsequent one six months later (validity).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2022
Typical duration for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 28, 2022
CompletedFirst Posted
Study publicly available on registry
October 6, 2022
CompletedStudy Start
First participant enrolled
November 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 13, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 13, 2025
CompletedNovember 4, 2025
October 1, 2025
2.6 years
September 28, 2022
October 31, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Interobserver agreement among readers regarding the clinical condition during the first evaluation point: at least three months after acute PE.
Based on a structured evaluation of clinical data generated during long term follow-up after PE and presented in a de-identified manner, six observers will independently categorize each patient as one of the following: 1. complete recovery from dyspnea and exercise intolerance to the state that pre-existed PE or dyspnea after PE but cardiopulmonary exercise test showing normal ventilatory dead space proportions (VD/VT) and normal estimated stroke volume augmentation (SVA) during exercise; 2. dyspnea after PE likely due to alternative diagnoses; 3. dyspnea after PE with increased VD/VT or decreased SVA during exercise in the presence of residual pulmonary vascular occlusion (RPVO) but without hemodynamic measurement; 4. symptomatic RPVO or chronic thromboembolic disease (CTED) documented by hemodynamic measurement; 5. chronic thromboembolic pulmonary hypertension (CTEPH) documented by hemodynamic measurement.
Each presentation will summarize clinical data leading up to and including an assessment time point at least 3 months after the onset of acute PE
Interobserver agreement among readers regarding clinical condition at the second evaluation point.
Based on a structured evaluation of clinical data generated during long term follow-up after PE and presented in a de-identified manner, six observers will independently categorize each patient as one of the following: 1. complete recovery from dyspnea and exercise intolerance to the state that pre-existed PE or dyspnea after PE but cardiopulmonary exercise test showing normal VD/VT and normal estimated SVA during exercise; 2. dyspnea after PE likely due to alternative diagnoses; 3. dyspnea after PE with increased VD/VT or decreased SVA during exercise in the presence of RPVO but without hemodynamic measurement; 4. symptomatic RPVO or CTED documented by hemodynamic measurement; 5. CTEPH documented by hemodynamic measurement; 6. death prior to the evaluation point.
Each presentation will summarize clinical data leading up to and including an assessment time point at least 6 months after the first assessment (described under Aim 1a)
Secondary Outcomes (1)
Constancy of diagnosis between first evaluation point and second evaluation point
Stability between the two time points will be determined after the presentation and evaluation of the 12-month time point
Study Arms (1)
Post-pulmonary embolism patients
Consecutive patients who, during the study period, underwent the SEARCH algorithm to a diagnostic endpoint at one of the UCAPE network of outpatient pulmonary embolism clinics (UC San Diego, UC Irvine, UC Los Angeles-Harbor, UC Los Angeles, UC Riverside, UC Davis, UC San Francisco or UC San Francisco-Fresno) three months or more after the occurrence of acute pulmonary embolism or any risk type. The SEARCH algorithm is the standard of care throughout the UCAPE network, so the experimental portion of this study is limited to the reporting of the (de-identified) results to the evaluation group and the analyses described in Aims 1 and 2. However, there may be patients who are lost to follow up or have other reasons for which the SEARCH algorithm is not followed. Those patients will not be included in the study. The numbers of such patients will be recorded at each center.
Interventions
The SEARCH algorithm is a structured, stepwise approach to follow up testing after acute PE that will enable timely diagnosis of post PE sequelae. The test results at each step inform the performance of the subsequent steps. The order of the tests in the algorithm uses the acronym SEARCH: Symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging, and hemodynamics.
Eligibility Criteria
The study will recruit consecutive patients who, during the study period, underwent the SEARCH algorithm at one of the UCAPE network of outpatient pulmonary embolism clinics (UC San Diego, UC Irvine, UCLA Harbor, UCLA, UC Riverside, UC Davis, UC San Francisco or UCSF Fresno) three months or more after the occurrence of acute pulmonary embolism or any risk type.
You may qualify if:
- age 18 years or greater
- objective evidence of acute pulmonary thrombo-embolism at least six months before the evaluation
- anticipated survival for at least three months
- a diagnostic endpoint in the SEARCH algorithm has been reached.
You may not qualify if:
- ● Cases in which the clinical presentations contain insufficient interpretable data to permit evaluation of SEARCH criteria, as described in the Study Design section, will be excluded from the analysis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of California, San Diegolead
- Inari Medicalcollaborator
Study Sites (8)
University of California, San Francisco-Fresno
Fresno, California, 93701, United States
University of California, Irvine
Irvine, California, 92868, United States
University of California, Los Angeles
Los Angeles, California, 90095, United States
University Hospital, Riverside
Moreno Valley, California, 92555, United States
University of California, Davis
Sacramento, California, 95817, United States
University of California, San Diego
San Diego, California, 92103, United States
University of California, San Francisco
San Francisco, California, 94143, United States
University of California, Los Angeles - Harbor
Torrance, California, 90502, United States
Related Publications (46)
DeMonaco NA, Dang Q, Kapoor WN, Ragni MV. Pulmonary embolism incidence is increasing with use of spiral computed tomography. Am J Med. 2008 Jul;121(7):611-7. doi: 10.1016/j.amjmed.2008.02.035.
PMID: 18589057BACKGROUNDKlok FA, Cohn DM, Middeldorp S, Scharloo M, Buller HR, van Kralingen KW, Kaptein AA, Huisman MV. Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire. J Thromb Haemost. 2010 Mar;8(3):523-32. doi: 10.1111/j.1538-7836.2009.03726.x. Epub 2009 Dec 15.
PMID: 20025645BACKGROUNDKlok FA, Tijmensen JE, Haeck ML, van Kralingen KW, Huisman MV. Persistent dyspnea complaints at long-term follow-up after an episode of acute pulmonary embolism: results of a questionnaire. Eur J Intern Med. 2008 Dec;19(8):625-9. doi: 10.1016/j.ejim.2008.02.006. Epub 2008 Apr 22.
PMID: 19046730BACKGROUNDKahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Geerts WH, Aaron SD, Granton JT. Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study. Chest. 2017 May;151(5):1058-1068. doi: 10.1016/j.chest.2016.11.030. Epub 2016 Dec 6.
PMID: 27932051BACKGROUNDKlok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Kaptein AA, Huisman MV. Quality of life in long-term survivors of acute pulmonary embolism. Chest. 2010 Dec;138(6):1432-40. doi: 10.1378/chest.09-2482. Epub 2010 May 21.
PMID: 20495104BACKGROUNDvan Es J, den Exter PL, Kaptein AA, Andela CD, Erkens PM, Klok FA, Douma RA, Mos IC, Cohn DM, Kamphuisen PW, Huisman MV, Middeldorp S. Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL. Thromb Res. 2013 Nov;132(5):500-5. doi: 10.1016/j.thromres.2013.06.016. Epub 2013 Oct 3.
PMID: 24090607BACKGROUNDTavoly M, Utne KK, Jelsness-Jorgensen LP, Wik HS, Klok FA, Sandset PM, Ghanima W. Health-related quality of life after pulmonary embolism: a cross-sectional study. BMJ Open. 2016 Nov 3;6(11):e013086. doi: 10.1136/bmjopen-2016-013086.
PMID: 27810979BACKGROUNDKahn SR, Akaberi A, Granton JT, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Hirsch AM. Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. Am J Med. 2017 Aug;130(8):990.e9-990.e21. doi: 10.1016/j.amjmed.2017.03.033. Epub 2017 Apr 8.
PMID: 28400247BACKGROUNDKlok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica. 2010 Jun;95(6):970-5. doi: 10.3324/haematol.2009.018960. Epub 2010 Jan 6.
PMID: 20053871BACKGROUNDFernandes TM, Alotaibi M, Strozza DM, Stringer WW, Porszasz J, Faulkner GG, Castro CF, Tran DA, Morris TA. Dyspnea Postpulmonary Embolism From Physiological Dead Space Proportion and Stroke Volume Defects During Exercise. Chest. 2020 Apr;157(4):936-944. doi: 10.1016/j.chest.2019.10.047. Epub 2019 Nov 22.
PMID: 31759962BACKGROUNDKlok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV. Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism. Respir Med. 2010 Nov;104(11):1744-9. doi: 10.1016/j.rmed.2010.06.006.
PMID: 20599368BACKGROUNDKlok FA, Zondag W, van Kralingen KW, van Dijk AP, Tamsma JT, Heyning FH, Vliegen HW, Huisman MV. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med. 2010 Mar 1;181(5):501-6. doi: 10.1164/rccm.200907-1141OC. Epub 2009 Dec 3.
PMID: 19965808BACKGROUNDBestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999 Jul;54(7):581-6. doi: 10.1136/thx.54.7.581.
PMID: 10377201BACKGROUNDRevicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008 Feb;61(2):102-9. doi: 10.1016/j.jclinepi.2007.03.012. Epub 2007 Aug 3.
PMID: 18177782BACKGROUNDCrisafulli E, Clini EM. Measures of dyspnea in pulmonary rehabilitation. Multidiscip Respir Med. 2010 Jun 30;5(3):202-10. doi: 10.1186/2049-6958-5-3-202.
PMID: 22958431BACKGROUNDKim JW, Clark A, Birring SS, Atkins C, Whyte M, Wilson AM. Psychometric properties of patient reported outcome measures in idiopathic pulmonary fibrosis. Chron Respir Dis. 2021 Jan-Dec;18:14799731211033925. doi: 10.1177/14799731211033925.
PMID: 34609156BACKGROUNDAlbaghdadi MS, Dudzinski DM, Giordano N, Kabrhel C, Ghoshhajra B, Jaff MR, Weinberg I, Baggish A. Cardiopulmonary Exercise Testing in Patients Following Massive and Submassive Pulmonary Embolism. J Am Heart Assoc. 2018 Mar 3;7(5):e006841. doi: 10.1161/JAHA.117.006841.
PMID: 29502109BACKGROUNDMcCabe C, Deboeck G, Harvey I, Ross RM, Gopalan D, Screaton N, Pepke-Zaba J. Inefficient exercise gas exchange identifies pulmonary hypertension in chronic thromboembolic obstruction following pulmonary embolism. Thromb Res. 2013;132(6):659-65. doi: 10.1016/j.thromres.2013.09.032. Epub 2013 Sep 27.
PMID: 24157082BACKGROUNDStringer WW, Hansen JE, Wasserman K. Cardiac output estimated noninvasively from oxygen uptake during exercise. J Appl Physiol (1985). 1997 Mar;82(3):908-12. doi: 10.1152/jappl.1997.82.3.908.
PMID: 9074981BACKGROUNDParaskos JA, Adelstein SJ, Smith RE, Rickman FD, Grossman W, Dexter L, Dalen JE. Late prognosis of acute pulmonary embolism. N Engl J Med. 1973 Jul 12;289(2):55-8. doi: 10.1056/NEJM197307122890201. No abstract available.
PMID: 4710405BACKGROUNDPrediletto R, Paoletti P, Fornai E, Perissinotto A, Petruzzelli S, Formichi B, Ruschi S, Palla A, Giannella-Neto A, Giuntini C. Natural course of treated pulmonary embolism. Evaluation by perfusion lung scintigraphy, gas exchange, and chest roentgenogram. Chest. 1990 Mar;97(3):554-61. doi: 10.1378/chest.97.3.554.
PMID: 2106409BACKGROUNDDonnamaria V, Palla A, Petruzzelli S, Carrozzi L, Pugliesi O, Giuntini C. Early and late follow-up of pulmonary embolism. Respiration. 1993;60(1):15-20. doi: 10.1159/000196167.
PMID: 8469816BACKGROUNDBass H, Banas JS Jr, Dalen JE. Pulmonary function studies. Aid to diagnosis of pulmonary embolism. Arch Intern Med. 1970 Aug;126(2):266-8. doi: 10.1001/archinte.126.2.266. No abstract available.
PMID: 5433065BACKGROUNDSharma GV, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med. 1980 Oct 9;303(15):842-5. doi: 10.1056/NEJM198010093031502.
PMID: 7412801BACKGROUNDHelmers RA, Zavala DC. Serial exercise testing in pulmonary embolism. Chest. 1988 Sep;94(3):517-20. doi: 10.1378/chest.94.3.517.
PMID: 3409730BACKGROUNDSanchez O, Helley D, Couchon S, Roux A, Delaval A, Trinquart L, Collignon MA, Fischer AM, Meyer G. Perfusion defects after pulmonary embolism: risk factors and clinical significance. J Thromb Haemost. 2010 Jun;8(6):1248-55. doi: 10.1111/j.1538-7836.2010.03844.x. Epub 2010 Mar 17.
PMID: 20236393BACKGROUNDPesavento R, Filippi L, Palla A, Visona A, Bova C, Marzolo M, Porro F, Villalta S, Ciammaichella M, Bucherini E, Nante G, Battistelli S, Muiesan ML, Beltramello G, Prisco D, Casazza F, Ageno W, Palareti G, Quintavalla R, Monti S, Mumoli N, Zanatta N, Cappelli R, Cattaneo M, Moretti V, Cora F, Bazzan M, Ghirarduzzi A, Frigo AC, Miniati M, Prandoni P; SCOPE Investigators. Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. Eur Respir J. 2017 May 25;49(5):1601980. doi: 10.1183/13993003.01980-2016. Print 2017 May.
PMID: 28546279BACKGROUNDWan T, Rodger M, Zeng W, Robin P, Righini M, Kovacs MJ, Tan M, Carrier M, Kahn SR, Wells PS, Anderson DR, Chagnon I, Solymoss S, Crowther M, White RH, Vickars L, Bazarjani S, Le Gal G. Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. Thromb Res. 2018 Feb;162:104-109. doi: 10.1016/j.thromres.2017.11.020. Epub 2017 Dec 8.
PMID: 29224973BACKGROUNDPengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 May 27;350(22):2257-64. doi: 10.1056/NEJMoa032274.
PMID: 15163775BACKGROUNDLeblanc M, Leveillee F, Turcotte E. Prospective evaluation of the negative predictive value of V/Q SPECT using 99mTc-Technegas. Nucl Med Commun. 2007 Aug;28(8):667-72. doi: 10.1097/MNM.0b013e32827a8e99.
PMID: 17625390BACKGROUNDBajc M, Olsson B, Palmer J, Jonson B. Ventilation/Perfusion SPECT for diagnostics of pulmonary embolism in clinical practice. J Intern Med. 2008 Oct;264(4):379-87. doi: 10.1111/j.1365-2796.2008.01980.x.
PMID: 18823506BACKGROUNDLemb M, Pohlabeln H. Pulmonary thromboembolism: a retrospective study on the examination of 991 patients by ventilation/perfusion SPECT using Technegas. Nuklearmedizin. 2001 Dec;40(6):179-86.
PMID: 11797505BACKGROUNDSoler X, Hoh CK, Test VJ, Kerr KM, Marsh JJ, Morris TA. Single photon emission computed tomography in chronic thromboembolic pulmonary hypertension. Respirology. 2011 Jan;16(1):131-7. doi: 10.1111/j.1440-1843.2010.01867.x.
PMID: 20920137BACKGROUNDSoler X, Kerr KM, Marsh JJ, Renner JW, Hoh CK, Test VJ, Morris TA. Pilot study comparing SPECT perfusion scintigraphy with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Respirology. 2012 Jan;17(1):180-4. doi: 10.1111/j.1440-1843.2011.02061.x.
PMID: 21899658BACKGROUNDGalie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29.
PMID: 26318161BACKGROUNDRibeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation. 1999 Mar 16;99(10):1325-30. doi: 10.1161/01.cir.99.10.1325.
PMID: 10077516BACKGROUNDRibeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997 Sep;134(3):479-87. doi: 10.1016/s0002-8703(97)70085-1.
PMID: 9327706BACKGROUNDRemy-Jardin M, Louvegny S, Remy J, Artaud D, Deschildre F, Bauchart JJ, Thery C, Duhamel A. Acute central thromboembolic disease: posttherapeutic follow-up with spiral CT angiography. Radiology. 1997 Apr;203(1):173-80. doi: 10.1148/radiology.203.1.9122389.
PMID: 9122389BACKGROUNDCosmi B, Nijkeuter M, Valentino M, Huisman MV, Barozzi L, Palareti G. Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. Intern Emerg Med. 2011 Dec;6(6):521-8. doi: 10.1007/s11739-011-0577-8. Epub 2011 Apr 3.
PMID: 21461909BACKGROUNDvan Es J, Douma RA, Kamphuisen PW, Gerdes VE, Verhamme P, Wells PS, Bounameaux H, Lensing AW, Buller HR. Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy. J Thromb Haemost. 2013 Apr;11(4):679-85. doi: 10.1111/jth.12150.
PMID: 23347140BACKGROUNDHallgren KA. Computing Inter-Rater Reliability for Observational Data: An Overview and Tutorial. Tutor Quant Methods Psychol. 2012;8(1):23-34. doi: 10.20982/tqmp.08.1.p023.
PMID: 22833776BACKGROUNDWitten L, Gardner R, Holmberg MJ, Wiberg S, Moskowitz A, Mehta S, Grossestreuer AV, Yankama T, Donnino MW, Berg KM. Reasons for death in patients successfully resuscitated from out-of-hospital and in-hospital cardiac arrest. Resuscitation. 2019 Mar;136:93-99. doi: 10.1016/j.resuscitation.2019.01.031. Epub 2019 Jan 30.
PMID: 30710595BACKGROUNDMoskowitz A, Omar Y, Chase M, Lokhandwala S, Patel P, Andersen LW, Cocchi MN, Donnino MW. Reasons for death in patients with sepsis and septic shock. J Crit Care. 2017 Apr;38:284-288. doi: 10.1016/j.jcrc.2016.11.036. Epub 2016 Dec 2.
PMID: 28013094BACKGROUNDSim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005 Mar;85(3):257-68.
PMID: 15733050BACKGROUNDRotondi MA, Donner A. A confidence interval approach to sample size estimation for interobserver agreement studies with multiple raters and outcomes. J Clin Epidemiol. 2012 Jul;65(7):778-84. doi: 10.1016/j.jclinepi.2011.10.019. Epub 2012 May 4.
PMID: 22560852BACKGROUNDMorris TA, Fernandes TM, Chung J, Vintch JRE, McGuire WC, Thapamagar S, Alotaibi M, Aries S, Dakaeva K. Observational cohort study to validate SEARCH, a novel hierarchical algorithm to define long-term outcomes after pulmonary embolism. BMJ Open. 2023 Sep 28;13(9):e074470. doi: 10.1136/bmjopen-2023-074470.
PMID: 37770267DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Timothy A Morris, MD
University of California, San Diego Healthcare
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine
Study Record Dates
First Submitted
September 28, 2022
First Posted
October 6, 2022
Study Start
November 15, 2022
Primary Completion
June 13, 2025
Study Completion
June 13, 2025
Last Updated
November 4, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share
There is not a plan to make individual participant data available.